-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 11, March 9, Zhongtian Pharmaceutical / Huashitong Biology 4 types of generic drug febuxostat tablets have been approved for marketing, approved for production and deemed to have been reviewed, the product is in 2019 The total market size of China's public medical institutions and physical pharmacies in cities in China in 2015 was close to 2 billion yuan.
Meinenet forecast data show that in 2020, the market size of terminal anti-gout preparations in physical pharmacies in Chinese cities will increase by 15.
64% year-on-year.
In the product ranking, febuxostat tablets are firmly at the top of the list.
Meinenet forecast data show that in 2020, the market size of terminal anti-gout preparations in physical pharmacies in Chinese cities will increase by 15.
64% year-on-year.
In the product ranking, febuxostat tablets are firmly at the top of the list.
Source: official website of the State Food and Drug Administration
Febuxostat tablet is a xanthine oxidase (XO) inhibitor that achieves curative effect by reducing serum uric acid.
It is mainly used for the long-term treatment of hyperuricemia in patients with gout.
It is known as the "gout drug".
It is mainly used for the long-term treatment of hyperuricemia in patients with gout.
It is known as the "gout drug".
According to data from Meinenet, the terminal sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 were close to 2 billion yuan.
New classification of febuxostat tablets production status
Source: One-click search on Mi Nei.
com
com
East Sunshine medicine, Yangtze River Pharmaceutical, medicine, and other special times of 11 companies submitted febuxostat by his new piece Classified listing application, Nanjing Heiner medicine , medicine transit / Hua Shi biological products have been approved and subject to With the same review, the products of other companies are still under review and approval.
Sales of terminal anti-gout preparations in physical pharmacies in cities in China
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In recent years, the market scale of terminal anti-gout preparations in Chinese urban physical pharmacies has been expanding, and the annual growth rate has remained at double digits.
Under the influence of the epidemic in 2020, the growth rate is expected to reach 15.
64%, and the market potential is great.
Under the influence of the epidemic in 2020, the growth rate is expected to reach 15.
64%, and the market potential is great.
TOP5 products of terminal anti-gout preparations in Chinese urban physical pharmacies
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Among the TOP5 products, febuxostat tablets ranked first, with sales exceeding 500 million yuan, a year-on-year increase of 22.
6%; benzbromarone tablets, which were approved by only two domestic enterprises for production, will also achieve a growth of 4.
67%.
6%; benzbromarone tablets, which were approved by only two domestic enterprises for production, will also achieve a growth of 4.
67%.
Medical Network News, March 11, March 9, Zhongtian Pharmaceutical / Huashitong Biology 4 types of generic drug febuxostat tablets have been approved for marketing, approved for production and deemed to have been reviewed, the product is in 2019 The total market size of China's public medical institutions and physical pharmacies in cities in China in 2015 was close to 2 billion yuan.
Meinenet forecast data show that in 2020, the market size of terminal anti-gout preparations in physical pharmacies in Chinese cities will increase by 15.
64% year-on-year.
In the product ranking, febuxostat tablets are firmly at the top of the list.
Meinenet forecast data show that in 2020, the market size of terminal anti-gout preparations in physical pharmacies in Chinese cities will increase by 15.
64% year-on-year.
In the product ranking, febuxostat tablets are firmly at the top of the list.
Source: official website of the State Food and Drug Administration
Febuxostat tablet is a xanthine oxidase (XO) inhibitor that achieves curative effect by reducing serum uric acid.
It is mainly used for the long-term treatment of hyperuricemia in patients with gout.
It is known as the "gout drug".
It is mainly used for the long-term treatment of hyperuricemia in patients with gout.
It is known as the "gout drug".
According to data from Meinenet, the terminal sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 were close to 2 billion yuan.
New classification of febuxostat tablets production status
Source: One-click search on Mi Nei.
com
com
East Sunshine medicine, Yangtze River Pharmaceutical, medicine, and other special times of 11 companies submitted febuxostat by his new piece Classified listing application, Nanjing Heiner medicine , medicine transit / Hua Shi biological products have been approved and subject to With the same review, the products of other companies are still under review and approval.
Sales of terminal anti-gout preparations in physical pharmacies in cities in China
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In recent years, the market scale of terminal anti-gout preparations in Chinese urban physical pharmacies has been expanding, and the annual growth rate has remained at double digits.
Under the influence of the epidemic in 2020, the growth rate is expected to reach 15.
64%, and the market potential is great.
Under the influence of the epidemic in 2020, the growth rate is expected to reach 15.
64%, and the market potential is great.
TOP5 products of terminal anti-gout preparations in Chinese urban physical pharmacies
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Among the TOP5 products, febuxostat tablets ranked first, with sales exceeding 500 million yuan, a year-on-year increase of 22.
6%; benzbromarone tablets, which were approved by only two domestic enterprises for production, will also achieve a growth of 4.
67%.
6%; benzbromarone tablets, which were approved by only two domestic enterprises for production, will also achieve a growth of 4.
67%.
Medical Network News, March 11, March 9, Zhongtian Pharmaceutical / Huashitong Biology 4 types of generic drug febuxostat tablets have been approved for marketing, approved for production and deemed to have been reviewed, the product is in 2019 The total market size of China's public medical institutions and physical pharmacies in cities in China in 2015 was close to 2 billion yuan.
Meinenet forecast data show that in 2020, the market size of terminal anti-gout preparations in physical pharmacies in Chinese cities will increase by 15.
64% year-on-year.
In the product ranking, febuxostat tablets are firmly at the top of the list.
Meinenet forecast data show that in 2020, the market size of terminal anti-gout preparations in physical pharmacies in Chinese cities will increase by 15.
64% year-on-year.
In the product ranking, febuxostat tablets are firmly at the top of the list.
Source: official website of the State Food and Drug Administration
Febuxostat tablet is a xanthine oxidase (XO) inhibitor that achieves curative effect by reducing serum uric acid.
It is mainly used for the long-term treatment of hyperuricemia in patients with gout.
It is known as the "gout drug".
It is mainly used for the long-term treatment of hyperuricemia in patients with gout.
It is known as the "gout drug".
According to data from Meinenet, the terminal sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 were close to 2 billion yuan.
Hospital hospital hospital pharmacy pharmacy pharmacy New classification of febuxostat tablets production status
Source: One-click search on Mi Nei.
com
com
East Sunshine medicine, Yangtze River Pharmaceutical, medicine, and other special times of 11 companies submitted febuxostat by his new piece Classified listing application, Nanjing Heiner medicine , medicine transit / Hua Shi biological products have been approved and subject to With the same review, the products of other companies are still under review and approval.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise Sales of terminal anti-gout preparations in physical pharmacies in cities in China
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In recent years, the market scale of terminal anti-gout preparations in Chinese urban physical pharmacies has been expanding, and the annual growth rate has remained at double digits.
Under the influence of the epidemic in 2020, the growth rate is expected to reach 15.
64%, and the market potential is great.
Under the influence of the epidemic in 2020, the growth rate is expected to reach 15.
64%, and the market potential is great.
TOP5 products of terminal anti-gout preparations in Chinese urban physical pharmacies
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Among the TOP5 products, febuxostat tablets ranked first, with sales exceeding 500 million yuan, a year-on-year increase of 22.
6%; benzbromarone tablets, which were approved by only two domestic enterprises for production, will also achieve a growth of 4.
67%.
6%; benzbromarone tablets, which were approved by only two domestic enterprises for production, will also achieve a growth of 4.
67%.
